Psyence Biomedical Ltd. to Conduct Phase IIb Trial for Alcohol Use Disorder
Ticker: PBMWW · Form: 6-K · Filed: Apr 11, 2025 · CIK: 1985062
Sentiment: neutral
Topics: clinical-trial, partnership, psychedelics, alcohol-use-disorder
TL;DR
Psyence Biomedical inks deal for Phase IIb trial on psilocybin for alcohol use disorder.
AI Summary
On April 2, 2025, Psyence Biomedical Ltd. announced a binding letter of intent (LOI) with Southern Star Research Pty Ltd for Psyence Australia Pty Ltd to conduct a Phase IIb clinical trial. This trial will investigate the efficacy of psilocybin in treating alcohol use disorder.
Why It Matters
This filing indicates Psyence Biomedical's progression in clinical trials for psilocybin-based treatments, potentially advancing the therapeutic landscape for alcohol use disorder.
Risk Assessment
Risk Level: medium — Clinical trial progression and regulatory approvals for novel treatments carry inherent risks.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant and parent company
- Psyence Australia Pty Ltd (company) — Wholly-owned subsidiary entering LOI
- Southern Star Research Pty Ltd (company) — Contract research organization (CRO) partner
- April 2, 2025 (date) — Date of LOI signing
FAQ
What is the purpose of the Phase IIb clinical trial mentioned in the filing?
The Phase IIb clinical trial will investigate the efficacy of psilocybin in treating alcohol use disorder.
Who is Psyence Biomedical Ltd. partnering with for this clinical trial?
Psyence Biomedical Ltd. is partnering with Southern Star Research Pty Ltd, a full-service Australian contract research organization (CRO).
What is the name of Psyence Biomedical Ltd.'s subsidiary involved in this agreement?
Psyence Australia Pty Ltd, a wholly-owned subsidiary of Psyence Biomedical Ltd., entered into the binding letter of intent.
When was the binding letter of intent (LOI) entered into?
The binding letter of intent was entered into on April 2, 2025.
What type of agreement was entered into between Psyence Australia Pty Ltd and Southern Star Research Pty Ltd?
A binding letter of intent (LOI) was entered into.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 11, 2025 regarding PSYENCE BIOMEDICAL LTD. (PBMWW).